Description

Repaglinide

• Class of medications: Antihyperglycemic agents known as meglitinides
• A rapid-acting insulin secretagogue that normalizes postprandial glucose excursions in type 2 diabetes mellitus patients.
• Reduces long-term cardiovascular complications of diabetes mellitus.
• Reduces blood glucose by stimulating insulin release from pancreatic beta-cells.
• Shows additive effects when used in combination with other oral antidiabetic agents.
• Reduces fasting and postprandial hyperglycemia and the level of glycosylated hemoglobin (HbA ₁c) in patients with T2DM.
• Its rapid onset and relatively short duration of action allow for flexible meal schedules.
• Equal efficacy to various sulphonylureas with a reduced risk of serious hypoglycemia and weight gain.